Early release rules for prisoners at end of life may be 'discriminatory,' say doctors

June 12, 2019

Doctors are calling for reform to rules governing when terminally ill prisoners are suitable for early release on compassionate grounds (ERCG) amid concerns that the current approach is discriminatory.

Data obtained from the UK Ministry of Justice and shared with The BMJ suggests that UK prisoners at the end of life are more likely to be granted ERCG if they have cancer than other conditions.

Jim Burtonwood, a palliative care specialty doctor who led the research, explains that under current legislation, the UK justice secretary can legally grant ERCG where there is a risk of harm to the prisoner from ongoing imprisonment, potential benefit through release, low risk of recidivism and adequate arrangements for safe care in the community.

But crucially, death must be expected "very soon" and HM Prisons and Probation Service consider this to be within three months.

Using Freedom Of Information requests to the Ministry of Justice, Burtonwood and colleagues found that in five years between 2013 and 2017, only 48 applications for ERCG were successful, while in the same period there were 845 recorded deaths from natural causes in prison.

What's more, in 2017, all six prisoners who had successful ERCGs had some form of cancer. This was despite the fact that 39% of all expected deaths from natural causes in English and Welsh prisons at that time were due to non-cancer causes, such as chronic lung disease (COPD) and dementia.

Burtonwood says the current ERCG legislation could be deemed to be discriminatory according to the 2010 Equality Act, and should be made more flexible.

"The rules as they stand favour those conditions like cancer with either clear prognoses or more predictable trajectories," he told The BMJ. "We saw that prisoner patients with COPD, dementia or heart failure were the ones that tended to be rejected, usually on the basis that their prognosis wasn't clear enough for people to make confident judgements about ERCG."

He acknowledges that decisions must be balanced against the risk of public harm, and notes that prison GPs may feel under pressure over making a definitive prognosis, because of the potential adverse publicity that could ensue if a patient lives longer than expected.

But he argues that for terminally ill prisoners, extending the ERCG requirement for a three month prognosis or recognising the uncertainty that comes with some of the non-cancer conditions "might help bring the UK into line with other European countries and allow for a more appropriate use of ERCG without adverse effects on public safety."

Current legislation regarding ERCG "appears to inadvertently treat patients differently according to their underlying diagnosis," he concludes. "It lies with clinical researchers to investigate the impact on patients, but with government and other policy makers to ensure parity of treatment through our laws."
-end-
Peer-reviewed? No
Type of evidence: Data analysis; Opinion
Subject: UK Ministry of Justice legislation

BMJ

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.